Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
Alessandro Dal MasoMartina LorenziAlessandra FerroSara PilottoFabiana CecereAlessandro FolladorValentina PoloAlessandro Del ConteGiulia SartoriMarco GiavarraDaniela ScattolinStefano IndraccoloStefano FregaGiovanna De MaglioJessica MenisLaura BonannoFiorella CalabreseValentina GuarneriPierFranco ConteGiulia PaselloPublished in: Future oncology (London, England) (2021)
Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns and treatment sequences. Patients & methods: This is a retrospective multicenter Italian observational study including consecutive Caucasian patients referred between 2014 and 2018. Results: 167 patients were included. Median progression-free survival was 9.8 months (95% CI: 8.3-13.3) for T790M+ and 6.0 months (95% CI: 4.9-7.2) for T790M- patients, respectively. Median overall survival was 20.7 months (95% CI: 18.9-28.4) for T790M+ and 10.6 months (95% CI: 8.6-23.6) for T790M- patients, respectively. The T790M mutation correlated with absence of new sites of disease. After progression, most T790M+ patients continued osimertinib, whereas most T790M- patients received a different treatment line. Conclusion: Better outcomes were shown in patients receiving osimertinib. A more limited progression pattern for T790M+ was suggested.
Keyphrases
- end stage renal disease
- chronic kidney disease
- small cell lung cancer
- ejection fraction
- newly diagnosed
- adipose tissue
- prognostic factors
- clinical trial
- type diabetes
- metabolic syndrome
- stem cells
- mesenchymal stem cells
- patient reported outcomes
- deep learning
- patient reported
- free survival
- electronic health record
- cross sectional
- cell therapy